Iveric Bio to Participate in the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference

Rhea-AI Summary

Iveric Bio (NASDAQ: ISEE) announced that its President, Pravin U. Dugel, M.D., will join a panel titled “Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE” at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference on August 17, 2022, at 9:00 a.m. ET. Investors can access the live webcast on the Iveric Bio website, with an archived replay available for 30 days post-conference. Iveric Bio focuses on developing innovative treatments for retinal diseases and is dedicated to improving patient outcomes.

PARSIPPANY, N.J.--(BUSINESS WIRE)-- IVERIC bio, Inc. (Nasdaq: ISEE) announced today that Pravin U. Dugel, M.D., President, will participate in a panel discussion titled, “Differentiation in Emerging Treatments for GA dAMD -- Perspectives From ISEE,” at the H.C. Wainwright 2^nd Annual Ophthalmology Virtual Conference on Wednesday, August 17, 2022, at 9:00 a.m. Eastern Time.

Investors and the general public are invited to access the live webcast of the panel discussion on the Investor / Events & Presentations section of the Iveric Bio website at www.ivericbio.com. An archived replay of the on-demand presentation will be available on the Company’s website immediately following the conference and for at least 30 days thereafter.

About Iveric Bio
Iveric Bio is a science-driven biopharmaceutical company focused on the discovery and development of novel treatments for retinal diseases with significant unmet medical needs. The Company is committed to having a positive impact on patients’ lives by delivering high-quality, safe and effective treatments designed to address debilitating retinal diseases including earlier stages of age-related macular degeneration. For more information on the Company, please visit www.ivericbio.com.

Forward-looking Statements

Any statements in this press release or made during the presentation referenced herein about Iveric Bio’s future expectations, plans and prospects constitute forward-looking statements for purposes of the safe harbor provisions under the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including those described in the “Risk Factors” section of public filings made by Iveric Bio with the U.S. Securities and Exchange Commission. Any forward-looking statements represent Iveric Bio’s views only as of the date of this press release or the presentation, as applicable. Iveric Bio anticipates that subsequent events and developments may cause its views to change. While Iveric Bio may elect to update these forward-looking statements at some point in the future, Iveric Bio specifically disclaims any obligation to do so unless required by law.

ISEE-G

View source version on businesswire.com: https://www.businesswire.com/news/home/20220802005782/en/

Investor Contact:

Kathy Galante

Senior Vice President, Investor Relations

kathy.galante@ivericbio.com

or

Media Contact:

Jeannie Neufeld

Senior Director, Public Relations and Communications

jeannie.neufeld@ivericbio.com

Source: IVERIC bio, Inc.

FAQ

What is the event featuring Iveric Bio on August 17, 2022?

Iveric Bio will participate in a panel discussion at the H.C. Wainwright 2nd Annual Ophthalmology Virtual Conference.

Who from Iveric Bio is speaking at the H.C. Wainwright Conference?

Pravin U. Dugel, M.D., President of Iveric Bio, will be speaking at the conference.

How can I watch Iveric Bio's panel discussion?

The panel discussion can be accessed via a live webcast on Iveric Bio's website.

Will there be a replay of Iveric Bio's presentation available?

Yes, an archived replay of the presentation will be available on the Iveric Bio website for at least 30 days after the conference.

What is Iveric Bio's focus in the biopharmaceutical industry?

Iveric Bio is focused on discovering and developing treatments for retinal diseases with significant unmet medical needs.